Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 6/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7653620 | 1.00 | CHRM2 (0.37) | CHRM2CHRM1CHRM3CHRM4MEN1 | |
| SCHEMBL6855572 | 1.00 | CHRM2 (0.37) | CHRM2CHRM1CHRM3CHRM4MEN1 | |
| SCHEMBL6861146 | 0.83 | CHRM2 (0.33) | CHRM2CHRM1CHRM3SLC1A2HRH3 | |
| SCHEMBL6863810 | 0.78 | SLC1A2 (0.48) | CHRM2CHRM1CHRM3CHRM4MEN1 | |
| SCHEMBL10581821 | 0.78 | SLC1A2 (0.48) | CHRM2CHRM1CHRM3CHRM4MEN1 | |
| SCHEMBL24039255 | 0.78 | MAPK1 (0.37) | CHRM2CHRM1CHRM3SLC1A2HRH3 | |
| SCHEMBL678255 | 0.78 | SLC1A2 (0.48) | CHRM2CHRM1CHRM3CHRM4MEN1 | |
| SCHEMBL16417261 | 0.78 | SLC1A2 (0.48) | CHRM2CHRM1CHRM3CHRM4MEN1 | |
| SCHEMBL5728913 | 0.77 | MAPK1 (0.37) | CHRM2CHRM1CHRM3SLC1A2HRH3 | |
| SCHEMBL2677786 | 0.76 | CHRM2 (0.35) | CHRM2CHRM1CHRM3SLC1A2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6797820-B2 | HYDROXAMATE DERIVATIVES THAT INHIBIT PEPTIDYL DEFORMYLASE (PDF), ANTIMICROBIALS AND ANTIBIOTICS | VICURON PHARMACEUTICALS INC. | 2004-09-28 | — | — | US | disclosed |
| EP-1237862-A1 | SUCCINATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AND PREPARATION | Versicor, Inc. (US) | 2002-09-11 | — | — | EP | disclosed |
| US-20020115863-A1 | Novel succinate compounds, compositions and methods of use and preparation | VICURON HOLDINGS LLC | 2002-08-22 | — | — | US | disclosed |
| WO-2001044179-A1 | NOVEL SUCCINATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AND PREPARATION | VERSICOR, INC. (US) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115863-A1 | Novel succinate compounds, compositions and methods of use and preparation | PDF, MMP2, SDHA | CHRM2 4834/4885CHRM1 4815/4885CHRM3 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.